Literature DB >> 18805096

The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.

Ilaria Napoli1, Valentina Mercaldo, Pietro Pilo Boyl, Boris Eleuteri, Francesca Zalfa, Silvia De Rubeis, Daniele Di Marino, Evita Mohr, Marzia Massimi, Mattia Falconi, Walter Witke, Mauro Costa-Mattioli, Nahum Sonenberg, Tilmann Achsel, Claudia Bagni.   

Abstract

Strong evidence indicates that regulated mRNA translation in neuronal dendrites underlies synaptic plasticity and brain development. The fragile X mental retardation protein (FMRP) is involved in this process; here, we show that it acts by inhibiting translation initiation. A binding partner of FMRP, CYFIP1/Sra1, directly binds the translation initiation factor eIF4E through a domain that is structurally related to those present in 4E-BP translational inhibitors. Brain cytoplasmic RNA 1 (BC1), another FMRP binding partner, increases the affinity of FMRP for the CYFIP1-eIF4E complex in the brain. Levels of proteins encoded by known FMRP target mRNAs are increased upon reduction of CYFIP1 in neurons. Translational repression is regulated in an activity-dependent manner because BDNF or DHPG stimulation of neurons causes CYFIP1 to dissociate from eIF4E at synapses, thereby resulting in protein synthesis. Thus, the translational repression activity of FMRP in the brain is mediated, at least in part, by CYFIP1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805096     DOI: 10.1016/j.cell.2008.07.031

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  262 in total

1.  nev (cyfip2) is required for retinal lamination and axon guidance in the zebrafish retinotectal system.

Authors:  Andrew J Pittman; John A Gaynes; Chi-Bin Chien
Journal:  Dev Biol       Date:  2010-06-09       Impact factor: 3.582

Review 2.  MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction.

Authors:  Bin Xu; Pei-Ken Hsu; Maria Karayiorgou; Joseph A Gogos
Journal:  Neurobiol Dis       Date:  2012-03-03       Impact factor: 5.996

3.  Rare CNVs and tag SNPs at 15q11.2 are associated with schizophrenia in the Han Chinese population.

Authors:  Qian Zhao; Tao Li; XinZhi Zhao; Ke Huang; Ti Wang; ZhiQiang Li; Jue Ji; Zhen Zeng; Zhao Zhang; Kan Li; GuoYin Feng; David St Clair; Lin He; YongYong Shi
Journal:  Schizophr Bull       Date:  2012-02-08       Impact factor: 9.306

Review 4.  Mechanisms of translational regulation in synaptic plasticity.

Authors:  Wayne S Sossin; Jean-Claude Lacaille
Journal:  Curr Opin Neurobiol       Date:  2010-04-27       Impact factor: 6.627

Review 5.  Regulation of translation initiation in eukaryotes: mechanisms and biological targets.

Authors:  Nahum Sonenberg; Alan G Hinnebusch
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

Review 6.  eIF4E: new family members, new binding partners, new roles.

Authors:  Robert E Rhoads
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

7.  TAR DNA-Binding Protein 43 and Disrupted in Schizophrenia 1 Coaggregation Disrupts Dendritic Local Translation and Mental Function in Frontotemporal Lobar Degeneration.

Authors:  Ryo Endo; Noriko Takashima; Yoko Nekooki-Machida; Yusuke Komi; Kelvin Kai-Wan Hui; Masaki Takao; Hiroyasu Akatsu; Shigeo Murayama; Akira Sawa; Motomasa Tanaka
Journal:  Biol Psychiatry       Date:  2018-03-29       Impact factor: 13.382

Review 8.  Emotional modulation of the synapse.

Authors:  Jayme R McReynolds; Christa K McIntyre
Journal:  Rev Neurosci       Date:  2012       Impact factor: 4.353

9.  Common EIF4E variants modulate risk for autism spectrum disorders in the high-functioning range.

Authors:  Regina Waltes; Johannes Gfesser; Denise Haslinger; Katja Schneider-Momm; Monica Biscaldi; Anette Voran; Christine M Freitag; Andreas G Chiocchetti
Journal:  J Neural Transm (Vienna)       Date:  2014-05-13       Impact factor: 3.575

Review 10.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.